KRAS G12C, which was found to be associated with smoking-associated signature 4 in lung adenocarcinoma (see above), also appears more strongly selected than other KRAS mutations (including G12D, G12R and G13D) in this cancer type (Fig. 3d, Supplementary Fig. 7). Here, KRAS is linked to lung adenocarcinoma.